

(d)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 November 2000 (16.11.2000)

PCT

(10) International Publication Number
WO 00/67762 A3

- (51) International Patent Classification⁷: A61K 33/04, (74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster LLP, 3811 Valley Centre Drive, Suite 500, San Diego, CA 92130-2332 (US).
- (21) International Application Number: PCT/US00/12828
- (22) International Filing Date: 11 May 2000 (11.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/133,678 11 May 1999 (11.05.1999) US
- (71) Applicant: ANTICANCER, INC. [US/US]; 7917 Ostrow Street, San Diego, CA 92111 (US).
- (72) Inventors: MIKI, Kenji; 8503 Villa La Jolla Drive, Apt. L., La Jolla, CA 92037 (US). XU, Mingxu; 4158 Decoro Street, Apt. 14, San Diego, CA 92122 (US). TAN, Yuying; 7575 Linda Vista Road, Apartment 80, San Diego, CA 92111 (US).
- (81) Designated States (*national*): AU, CA, JP.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:
— *With international search report.*
- (88) Date of publication of the international search report: 19 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/67762 A3

(54) Title: SelenIUM-CONTAINING PRO-DRUGS FOR CANCER THERAPY

(57) Abstract: Methods for inhibiting the growth of tumor cells by combination treatment with a selenium-containing prodrug and an enzyme for which it is a substrate are described. The treatment also enhances the effect of anti-tumor agents.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/12828

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	A61K33/04	A61K38/51	A61P35/00	A61K31/198	A61K48/00
-------	-----------	-----------	-----------	------------	-----------

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>MIKI KENJI ET AL: "Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), page 670 XP002153731</p> <p>91st Annual Meeting of the American Association for Cancer Research.; San Francisco, California, USA; April 01-05, 2000, March, 2000</p> <p>ISSN: 0197-016X</p> <p>abstract</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-3, 5, 6, 8-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 November 2000

Date of mailing of the International search report

13/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Noë, V

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/12828

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NICULESCU-DUVAZ I ET AL: "GENE-DIRECTED ENZYME PRODRUG THERAPY" BIOCONJUGATE CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 9, no. 1, 1998, pages 4-22, XP000729231 ISSN: 1043-1802 the whole document -----	1-13
A	US 5 783 454 A (REID TED W ET AL) 21 July 1998 (1998-07-21) the whole document -----	
A	DACHS G U ET AL: "Targeting gene therapy to cancer: a review" ONCOLOGY RESEARCH, PERGAMON PRESS, NEW YORK, NY, US, vol. 9, no. 9, 1997, pages 313-325, XP002096474 ISSN: 0965-0407 the whole document -----	
A	WO 94 11535 A (ANTICANCER INC ;LISHKO VALERYI (US)) 26 May 1994 (1994-05-26) the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

 Inte^l mal Application No

PCT/US 00/12828

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5783454	A	21-07-1998	AU	2588495 A	05-12-1995
			EP	0804247 A	05-11-1997
			JP	10500410 T	13-01-1998
			US	6043098 A	28-03-2000
			US	6033917 A	07-03-2000
			US	6040197 A	21-03-2000
			US	6043099 A	28-03-2000
			US	6077714 A	20-06-2000
			US	5994151 A	30-11-1999
			WO	9531218 A	23-11-1995
WO 9411535	A	26-05-1994	AU	687768 B	05-03-1998
			AU	5615494 A	08-06-1994
			CA	2149776 A	26-05-1994
			EP	0668933 A	30-08-1995
			JP	2930723 B	03-08-1999
			JP	8507287 T	06-08-1996
			US	5690929 A	25-11-1997
			US	5715835 A	10-02-1998
			US	5891704 A	06-04-1999
			US	5888506 A	30-03-1999

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 33/04, 38/51, A61P 35/00		A2	(11) International Publication Number: WO 00/67762 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/US00/12828 (22) International Filing Date: 11 May 2000 (11.05.00)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/133,678 11 May 1999 (11.05.99) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: ANTICANCER, INC. [US/US]; 7917 Ostrow Street, San Diego, CA 92111 (US).			
(72) Inventors: MIKI, Kenji; 8503 Villa La Jolla Drive, Apt. L., La Jolla, CA 92037 (US). XU, Mingxu; 4158 Decoro Street, Apt. 14, San Diego, CA 92122 (US). TAN, Yuying; 7575 Linda Vista Road, Apartment 80, San Diego, CA 92111 (US).			
(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).			

(54) Title: SELENIUM-CONTAINING PRO-DRUGS FOR CANCER THERAPY

(57) Abstract

Methods for inhibiting the growth of tumor cells by combination treatment with a selenium-containing prodrug and an enzyme for which it is a substrate are described. The treatment also enhances the effect of anti-tumor agents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

SELENIUM-CONTAINING PRO-DRUGS FOR CANCER THERAPY

Cross-Reference to Related Applications

This application claims priority from Provisional Application 60/133,678 filed 11 May 1999. The contents of that application are incorporated herein by reference.

5 Technical Field

The invention relates to the use of the combination of a lyase with a selenium-containing lyase substrate to inhibit or destroy tumor cells *in vitro* and *in vivo*. More specifically, the invention concerns providing an enzyme capable of generating a toxic selenium form from a relatively nontoxic substrate in combination with said substrate. An illustrative 10 combination is selenomethionine in combination with methioninase. The enzyme may be supplied directly or generated recombinantly *in situ*.

Background Art

Selenium is an element essential for metabolism, but in the wrong form and in inappropriate amounts it is cytotoxic. This may be advantageous in the context of 15 carcinostatic properties. Spallholz, J.E., in a review article published in *Free Radical Biology and Medicine* (1994) 17:45-64, proposed that the toxic selenium species is the metabolic selenide RSe⁻ anion. The anion can participate in transthiolation reactions and generate superoxide, hydrogen peroxide and perhaps other cascading oxyradicals, according to this proposal. In a later paper from the same group, Stewart, M.J., *et al.*, *Free 20 Radical Biology and Medicine* (1999) 26:42-48, it is reported that catalytic selenite, selenocystine and selenocystamine induced apoptosis and were cytotoxic in keratinocytes, but selenomethionine was not cytotoxic and did not induce cellular apoptosis at the concentrations studied. Selenomethionine has also been shown to act as a cancer chemoprotectant by Ip, *et al.*, *Cancer Res.* (1990) 50:1206-1211; El-Bayoumy, K., *et al.*, *Cancer Res.* (1992) 52:2402-2407. Selenium compounds shown to inhibit carcinogenesis 25 in rodents have been reported by Yan, Y., *et al.*, *Biochem. Pharmacol.* (1993) 45:429-437. Apparently, diselenide forms of organic selenium compounds, such as selenocystine and selenocystamine can be converted to the toxic form RSe⁻. However, mammalian cells do

not readily convert the monoselenide forms to toxic moieties. Thus, selenomethionine, selenohomocysteine and selenocysteine are relatively nontoxic and noncarcinostatic. Selenodithiols have been used to inhibit proliferation of cancer cells as described in U.S. Patent 5,104,852 and selenium compounds which would otherwise be toxic have been 5 used therapeutically in small enough concentrations as described in U.S. Patent 4,512,977. It has now been found that a particularly effective protocol for treatment of tumors comprises using the nontoxic forms of selenium as pro-drugs when the targeted cells are provided with a means to convert the pro-drugs to the toxic forms. The pro-drugs themselves can be cytotoxic if at sufficiently high levels. Kajander, E.O., *et al.*, *Biochem J.* (1990) 267:767-774. However, these levels are several orders of magnitude higher than 10 those required for cytotoxicity of compounds that can readily generate RSe⁻ in cells.

Disclosure of the Invention

The invention is directed to protocols and formulations for selectively killing cancer cells through the combination of an RSe⁻ generating enzyme, such as methioninase and its 15 selenium-containing substrate, e.g., selenomethionine. The method can be used in chemotherapy regimen to treat a variety of cancers. The selenium-containing prodrug and/or the methioninase can also be selectively targeted to a particular cancer cell type or to a tumor site. The methioninase can be administered as a nucleic acid comprising a nucleotide sequence which encodes the enzyme that is expressible by the cancer cells or by 20 other target host cells. The methioninase and the selenium-containing prodrug can also be directly administered to the tumor site, where possible or desired. The protocols cause cell death or retard cell growth.

The selenium-containing prodrugs include selenomethionine and related compounds. The prodrug is cleaved by a lyase at the C-Se bond to result in the release of the active selenide 25 moiety. This moiety is thought to be a methylselenide or a related compound of the formula RSe⁻ where R is hydrocarbyl or H.

The enzyme administered will be one which serves as a lyase for the selenium-containing prodrug. If the selenium-containing prodrug is selenomethionine, methioninase is an appropriate choice.

30 Methioninase can be recombinantly produced or purified from natural sources. For example see U.S. Patent 5,690,929. An expression system or cassette for production of

methioninase can be used in place of the enzyme or along with it if desired. The vector permits the selective expression of the enzyme, which would localize its presence at a selected or desired site. Further, the methioninase can be complexed with a targeting molecule, e.g. an antibody that recognizes cancer cells. See, e.g. U.S. Patent

5 No. 5,057,313. The selenium-containing prodrug can similarly be targeted.

Thus, in one aspect, the invention is directed to a method to inhibit tumor cell growth which method comprises contacting said tumor cells with a selenium-containing prodrug and with an enzyme that liberates a toxic form of selenium from said prodrug in amounts sufficient to inhibit said tumor cell growth. In a preferred embodiment, the enzyme is an
10 α,γ -lyase or an α,β -lyase and the selenium-containing prodrug is a corresponding sulfur-containing amino acid or the corresponding amine. In one preferred embodiment, the lyase is supplied by generating it internally to the targeted tumor cells or in cells adjacent to them by providing a suitable expression system to said cells or their neighbors.

Brief Description of the Drawings

15 Figure 1 shows a diagram of the vector used for production of methioninase *in situ*, pQBI-Ad CMV 5MET.

Figure 2 shows the effect of various virus titers of the methioninase-providing virus on cell survival in the presence and absence of SeMet using OVCAR-8 cells.

20 Figure 3 shows the effect of various virus titers of the methioninase-providing virus on cell survival in the presence and absence of SeMet using A204 cells.

Figure 4 shows the effect of various virus titers of the methioninase-providing virus on cell survival in the presence and absence of SeMet using PC-3 cells.

Figure 5 shows the effect of various virus titers of the methioninase-providing virus on cell survival in the presence and absence of SeMet using A549 cells.

25 Figure 6 shows the effect of SeMet concentration on OVCAR-8 cells transduced with rAd-MET.

Figure 7 shows the combined effect of various concentrations of SeMet and various titers of control rAd on cell survival for A549 cells.

30 Figure 8 shows the combined effect of concentration of SeMet and virus titers for rAd-MET on survival of A549 cells.

Figure 9 shows the bystander effect of rAd-MET and SeMet in combination on A549 cells.

Figure 10 shows the induction of apoptosis by the combination of rAd-MET and SeMet on A549 cells.

Figure 11 shows the generation of oxidant by rAd-MET in combination with SeMet as detected by chemiluminescence of lucigenin.

5 Figure 12 shows the effect of the combination of SeMet and rAd-MET on caspase concentrations in lysates of A549 cells.

Figure 13 shows the effect of the combination of rAd-MET and SeMet on ascites tumor growth *in vivo*.

10 Figure 14 shows the effect of the combination of rAd-MET and SeMet on survival of nude mice containing ascites tumors.

Modes of Carrying Out the Invention

It is understood that the toxicity of a selenium-based compound is highly dependent on the nature of the compound. Certain selenium compounds which are able to generate selenium anions of the general formula RSe⁻ where R is H or a hydrocarbyl substituent are 15 highly toxic. Forms of selenium which are known to be capable of generating this toxic moiety include the inorganic moiety selenite and organic diselenide compounds such as selenocystamine and selenocystine. However, other compounds, in particular the selenated forms of the sulfur-containing amino acids homocysteine, cysteine and methionine and their corresponding decarboxylated forms do not generate the toxic form 20 of selenium in mammalian cells.

However, there are a number of enzymes derivable from non-mammalian sources that are able to lyse these substrates and generate toxic forms of selenium. These enzymes include L-methionine γ -lyase from *Aeromonas* (Nakayama, T., *et al.*, *Agric. Biol. Chem.* (1984) 48:2367-2369) which utilizes methionine, ethionine, homocysteine and acetyl 25 L-homoserine as substrates; the methionine γ -lyase from *Pseudomonas putida* described by Nakayama, T., *et al.*, *Analyt. Biochem.* (1984) 138:421-424, which has a similar substrate spectrum; and the L-methionine γ -lyase from *Pseudomonas ovalis*, Tanaka, H., *et al.*, *Biochemistry* (1977) 16:100-106. A detailed description of these enzymes 30 (EC 4.4.1.11) is found in an article by Esaki, N., *et al.*, *Methods in Enzymology* (1987) 143:459-465. The anti-tumor activity of this enzyme itself has been described by Tanaka, H., *et al.*, *J. Applied Biochem.* (1980) 2:439-444 and the gene encoding the *P. putida*

enzyme as well as other corresponding enzymes have been cloned. See Inoue, H., *et al.*, *J. Biochem.* (1995) 117:1120-1125. See also PCT publication WO 99/05311 and US Patents 5,861,154 and 5,863,788. The ability of the methionine γ -lyase from *P. putida* to catalyze the replacement of the methylthio moiety in methionine to obtain the corresponding

5 selenium-containing form has also been disclosed by Esaki, N., *et al.*, *Biochemistry* (1979) 18:407-411. It appears, based on the results described in this paper, that amino acids other than methionine wherein the methyl group is replaced by an alkyl substituent or even a phenyl or benzyl substituent are suitable substrates for this enzyme.

Thus, the selenium-containing prodrug may be any selenium-containing compound that

10 can behave as a substrate for an appropriate enzyme to generate the toxic form of selenium, believed to be RSe⁻ wherein R is H or hydrocarbyl, typically alkyl, phenyl or benzyl. The nature of this group is dependent only on the specificity of the enzyme.

The enzyme is typically a lyase of the type described above. However, any enzyme which dissociates the selenium-containing prodrug to generate the toxic selenium form is

15 workable in the method of the invention. Such enzymes are referred to herein as "selenium prodrug lyase(s)."

The selenium prodrug lyase may be supplied as a protein or may be generated intracellularly or *in situ* by supplying an expression system for the enzyme. If the enzyme *per se* is administered, methods for administering such proteins are generally known in the

20 art. For example, methods to administer methioninase in particular, in the context of chemotherapy are set forth in U.S. Patent 5,690,929, the contents of which are incorporated herein by reference. Proteins in general can be administered by injection, typically intravenous injection or by transmembrane administration, for example, intranasally or using suppositories. Other modes of administration are also possible,

25 including oral administration provided adequate protection from hydrolysis is included in the formulation. Such methods are generally known in the art as described in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton PA.

The protein may be administered *per se* or it may also include a targeting agent to direct the protein specifically to tumor cells. Such targeting agents may include, for example, 30 antibodies or immunologically reactive fragments thereof, including single-chain antibodies, which are immunospecific for antigens associated with tumor cells or for

antigens which appear on the organs in which the tumors reside, such as prostate-specific antigen in the case of prostate cancer. In addition, the targeting agents may include ligands for receptors that characterize the cells associated with the tumor. Coupling to such targeting agents is also conventional and involves standard linking technologies, 5 optionally utilizing commercially available linkers, such as those available from Pierce Chemical Company, Rockford IL.

If the selenium prodrug lyase is to be generated intracellularly or *in situ*, a suitable nucleic acid molecule containing the nucleotide sequence encoding the enzyme is administered. Suitable modes of administration include injection, topical administration in formulations 10 that include agents which enhance transmembrane or transdermal transit or any other appropriate and convenient method consistent with the situs of the tumor cells and the nature of the formulation, as will be understood by the ordinary practitioner. One particularly preferred mode of administration is local to the tumor - *i.e.*, the nucleic acid molecule may be administered directly to the tumor tissue or to the site where the tumor 15 resides. Because the formulations of the invention are able to provide not only a cytotoxic effect on the cells containing the prodrug and enzyme but also a bystander effect on neighboring cells, direct administration to the locus of the tumor is often satisfactory. The nucleic acid molecule is typically a vector, most commonly a viral vector, although naked DNA can, in some instances, be used. The viral vectors may be retroviral vectors, 20 which preferentially replicate in rapidly proliferating cells, thus conferring specificity for tumor cells on the vector, or may include adenoviral vectors or other conventional vector-based molecules. Specificity in this case may be conferred by localized administration and/or by placing the expression of the nucleotide sequence encoding the enzyme under control of a promoter which is operable selectively in tumor tissue. Table 1 below sets 25 forth a list of tumor-associated viruses and oncogenes which comprise promoters specific for the tumors with which they are associated. Promoters associated with these genes and viruses may be used to direct expression selectively in the appropriate tumor.

Table 1. Oncogenes and tumor viruses

Acronym	Virus	Species	Tumor origin	Comments
<i>abl</i>	Abelson leukemia	Mouse	Chronic	TyrPK(src)

Table 1. Oncogenes and tumor viruses

Acronym	Virus	Species	Tumor origin	Comments
			myelogenous leukemia	
<i>erbA</i>	Erythroblastosis	Chicken		Homology to human glucocorticoid receptor
<i>erbB</i>	Erythroblastosis	Chicken		TyrPK EGF/TGF β receptor
<i>ets</i>	E26 myeloblastosis	Chicken		Nuclear
<i>fes (fps)^a</i>	Snyder-Thellen sarcoma	Cat		TyrPK(src)
	Gardner-Arnstein sarcoma			
<i>fgr</i>	Gardner-Rasheed sarcoma	Cat		TyrPK(src)
<i>fms</i>	McDonough sarcoma	Cat		TyrPK CSF-1 receptor
<i>fps (fes)^a</i>	Fujinami sarcoma	Chicken		TyrPK(src)
<i>fos</i>	FBJ osteosarcoma	Mouse		Nuclear, TR
<i>hst</i>	NVT	Human	Stomach tumor	FGF homologue
<i>intl</i>	NVT	Mouse	MMTV-induced carcinoma	Nuclear, TR
<i>int2</i>	NVT	Mouse	MMTV-induced carcinoma	FGF homologue
<i>jun</i>	ASV17 sarcoma	Chicken		Nuclear, TR
<i>hit</i>	Hardy-Zuckerman 4 sarcoma	Cat		TyrPK GFR L
<i>B-lym</i>	NVT	Chicken	Bursal lymphoma	

Table 1. Oncogenes and tumor viruses

Acronym	Virus	Species	Tumor origin	Comments
<i>mas</i>	NVT	Human	Epidermoid carcinoma	Potentiates response to angiotensin II
<i>met</i>	NVT	Mouse	Osteosarcoma	TyrPK GFR L
<i>mil (raf)^b</i>	Mill Hill 2 acute leukemia	Chicken		Ser/ThrPK
<i>mos</i>	Moloney sarcoma	Mouse		Ser/ThrPK
<i>myb</i>	Myeloblastosis	Chicken	Leukemia	Nuclear, TR
<i>myc</i>	MC29 myelocytomatosis	Chicken	Lymphomas	Nuclear TR
<i>N-myc</i>	NVT	Human	Neuroblastomas	Nuclear
<i>neu (ErbB2)</i>	NVT	Rat	Neuroblastoma	TryPK GFR L
<i>ral (mil)^b</i>	3611 sarcoma	Mouse		Ser/ThrPK
<i>Ha-ras</i>	Harvey murine sarcoma	Rat	Bladder, mammary and skin carcinomas	GTP-binding
<i>Ki-ras</i>	Kirsten murine sarcoma	Rat	Lung, colon carcinomas	GTP-binding
<i>N-ras</i>	NVT	Human	Neuroblastomas leukaemias	GTP-binding
<i>rel</i>	Reticuloendotheliosis	Turkey		
<i>ros</i>	UR2	Chicken		TyrPK GFR L
<i>sis</i>	Simian sarcoma	Monkey		One chain of PDGF
<i>src</i>	Rous sarcoma	Chicken		TyrPK
<i>ski</i>	SKV770	Chicken		Nuclear
<i>trk</i>	NVT	Human	Colon carcinoma	TyrPK GFR L
<i>yes</i>	Y73, Esh sarcoma	Chicken		TyrPK(src)

Suitable viral vector constructs are those known in the art. For example, vectors derived from a parvovirus (U.S. Patent Nos. 5,252,479 and 5,624,820), a paramyxovirus such as simian virus 5 (SV5) (U.S. Patent No. 5,962,274), a retrovirus such as HIV (U.S. Patent Nos. 5,753,499 and 5,888,767), and a baculovirus such as a nuclear polyhedrosis virus (U.S. Patent No. 5,674,747) can be used. Vectors derived from adenovirus have been extensively studied (U.S. Patent Nos. 5,670,488, 5,817,492, 5,820,868, 5,856,152 and 5,981,225 all incorporated herein by reference).

The nucleic acid molecule can be delivered directly to a tissue of the host animal by injection, by gene gun technology or by lipid mediated delivery technology. The injection can be conducted via a needle or other injection devices. The gene gun technology is disclosed in U.S. Patent No. 5,302,509 and the lipid mediated delivery technology is disclosed in U.S. Patent No. 5,703,055.

In still another specific embodiment, the nucleic acid molecule is delivered to a cell of host animal *ex vivo* and the cell is then delivered to a suitable tissue of the host animal, preferably through injection or intravenous drip.

General methods for *ex vivo* transduction and whole animal administration include $\text{Ca}_3(\text{PO}_4)_2$ -DNA transfection (Sambrook, *et al.*, *Molecular Cloning*, 2nd Edition, Plainview, N.Y. Cold Spring Harbor Press, 1989), DEAE dextran-DNA transfection (Sambrook, *et al.*, *Molecular Cloning*, 2nd Edition, Plainview, N.Y. Cold Spring Harbor Press, 1989), electroporation (*e.g.*, protocols from Bio-Rad), transfection using "LIPOFECTIN"™ reagent (*e.g.*, protocols from BRL-Life Science), gene gun technology (U.S. Patent No. 5,302,509), or viral gene delivery system (Kaplitt, *et al.*, *Viral Vectors*, Academic Press, Inc., 1995).

Although the prodrug and the selenium prodrug lyase may be delivered concomitantly, it is preferred that the enzyme be provided first, followed by administration of the selenium-containing prodrug. This is in order that the cells will be preconditioned to generate the toxic form of selenium. In any event, the tumor to be treated must be proximal both to the lyase and the prodrug to elicit the toxic response.

In addition to the selenium-containing prodrug and the prodrug lyase, chemotherapeutic agents can be employed in suitable therapeutic protocols. Such agents as 5-FU, cyclophosphamide, doxorubicin, BCNU, methotrexate and other drugs may be employed

along with the protocols of the invention. The efficacy of these drugs is enhanced by the lyase and the prodrug.

The tumors to be treated may include solid tumors such as those of the breast, prostate, colon, lung, brain, pancreas, liver, and the like or may be lymphomas or other leukemias
5 or metastases of solid tumors. The selection of the appropriate expression system both from the standpoint of the vector and the control sequences for expression will depend on the nature of the tumor targeted. The nucleotide sequence encoding the enzyme may also be provided with a fusion amino acid sequence which confers target specificity, as was the case for direct administration of the enzyme.

10

The following examples are intended to illustrate but not to limit the invention.

Example 1

Construction of a Methioninase-Producing Vector

Figure 1 shows a diagram of a vector constructed to provide viral infection of tumor cells
15 and expression the methioninase derived from *P. putida*. The nucleotide sequence encoding the enzyme is placed under control of the CMV-5 promoter and enhancer. The backbone vector is commercially available. The resulting vector is propagated according to standard techniques in adenovirus.

To prepare the vector, the methioninase gene cloned from *P. putida* as described in Inoue,
20 H., et al, *J.Biochem* (1995) 117:1120-1125 was amplified by PCR and the 1.2 kb gene was ligated into the transfer vector pQBI-Ad CMV 5GFP (obtained from Quantum, Montreal, Quebec, Canada) downstream of the CMV-5 promoter at the BglII/PmeI site. The resulting vector is shown in figure 1. The vector was cotransfected into 293A cells (Quantum) using the calcium phosphate method along with Ad CMV Lac ZΔE1/Δ3 viral
25 DNA cut with Clal (Quantum). Transfected cells were overlain with 1.25% Sea Plaque agarose (FMC Bioproducts, Rockland, ME) and incubated at 37°C for 14-21 days. Primary plaques were isolated and used to infect 293A cells to generate primary crude viral lysate. Methioninase gene expression in the viral lysate was confirmed by an enzymatic assay. After a second plaque purification, a single plaque was amplified in
30 293A cells. Ad CMV 5GFP ΔE1/ΔE3 was used as a control vector (-rAd) and purchased

from Quantum. The control rAd was expanded in 293A cells and purified by cesium chloride centrifugation and subsequent fractionation on Sephadex G25. The above-described construction of rAd-MET is reported by Miki, K., *et al.*, *Cancer Res.* (in press) incorporated herein by reference.

5

Example 2

Effect of Varying Methioninase in the Presence of Selenomethionine on Various Tumor Cell Lines

- Cells (4×10^3) of various tumor lines were seeded onto 96-well plates. After 24 hours, serial dilutions of the methioninase expressing vector (rAd-MET) or a control vector containing no methioninase encoding nucleotide sequence (rAd) were added to the wells with and without 20 μM of selenomethionine (SeMet) (20 μM). After incubating the plates for three (3) days, the medium was replaced with 0.5 mg/ml MTT for two (2) hours and analyzed using a microplate reader (BioRad), in a standard MTT assay. Results were recorded as percentage of surviving cells.
- 15 The cell lines tested were human cancer cell lines OVCAR-8 (ovarian cancer), A549 and EKVX (lung cancer), Hep-2 (head and neck cancer), MIA PaCa-2 and BxPC-3 (pancreatic cancer), human rhabdomyosarcoma cell line A204 and human prostate cell line PC-3. The results with respect to the OVCAR-8 cell line and cell lines A204, and PC-3 are shown in figures 2, 3 and 4 in X/Y graphs; figure 5 is a bar graph of the results with respect to the 20 A549 cell line. In each case, the presence of SeMet drastically lowered the IC_{50} for the rAd-MET vector. The results are further summarized in Table 1.

Table 1

**Comparison of IC₅₀ of rAd-MET and Control-rAd in human tumor cell lines
with or without SeMet**

cell lines	IC ₅₀ rAd-MET (pfu)		IC ₅₀ Control-rAd (pfu)	
	SeMet (+)	SeMet (-)	SeMet (+)	SeMet (-)
OVCAR-8	2.7 x 10 ³	3.0 x 10 ⁵	3.8 x 10 ⁶	4.6 x 10 ⁶
A549	7.0 x 10 ³	3.3 x 10 ⁵	6.7 x 10 ⁵	8.0 x 10 ⁵
Hep-2	5.9 x 10 ³	3.3 x 10 ⁵	7.9 x 10 ⁵	5.9 x 10 ⁵
MIA PaCa-2	1.7 x 10 ⁴	3.6 x 10 ⁵	9.3 x 10 ⁵	1.1 x 10 ⁶
BxPC-3	3.5 x 10 ⁴	3.1 x 10 ⁶	2.7 x 10 ⁶	3.0 x 10 ⁶
EKVVX	3.7 x 10 ³	4.8 x 10 ⁵	1.2 x 10 ⁶	1.7 x 10 ⁶

As seen from the table, the IC₅₀ values in the presence, as compared to the absence, of SeMet are approximately two orders of magnitude less for all cell lines. rAd-MET, as expected, even in the absence of SeMet has some effect.

5

Example 3

Effect of Varying SeMet in the Presence of Methioninase

The cell lines were also evaluated for their response to varying concentrations of SeMet. In these protocols, the cells were seeded as above into 96-well plates and infected with 4 x 10⁵ pfu of rAd-MET or control rAd. After 24 hours, serial dilutions of SeMet were added and three (3) days later cytotoxicity was evaluated with the MTT assay as described in Example 2. The results are shown for OVCAR-8 cells in figure 6. As seen, the IC₅₀ for SeMet is lowered over a thousandfold in the presence of rAd-MET as compared to control rAd. A summary of the IC₅₀ values for a number of cell lines is shown in Table 2.

10

Table 2**Comparison of SeMet IC₅₀ in human tumor cell lines transduced with rAd-MET**

cell lines	SeMet IC ₅₀ (μM)		
	rAd-MET	Control-rAd	Wild Type
OVCAR-8	0.59	170.3	223.6
A549	0.5	327.1	485.9
Hep-2	1.66	387	411
MIA PaCa-2	3.86	338	422
BxPC-3	3.38	222.6	311.8
EKVX	1.66	686.4	1360

Virtually all cell lines showed a dramatic decrease in IC₅₀ for SeMet in the presence of rAd-MET.

Example 4

5

Combined Variation of rAd-MET and SeMet on A549 Cells

The experiments described in Examples 2 and 3 were performed on A549 human lung cancer cells using varying concentrations of SeMet from 0-40 μM and of virus rAd-MET titer of 0-8 × 10⁵ pfu using rAd as a control. Percentage of surviving cells was again used as an index of efficacy.

10 As shown in figure 7, when the control vector was employed, the virus titer was substantially irrelevant to the results. Selenomethionine itself showed slight toxicity at 20-40 μM.

However, as shown in figure 8, when rAd-MET was provided, even at virus titers of 5,000 pfu, 20-40 μM of SeMet drastically reduced viability. At virus titers of 4 × 10⁵, even

15 2.5 μM SeMet provided toxicity such that only 50% of the cells survived. At 8 × 10⁵ pfu, the vector alone was sufficient to be cytotoxic, but concentrations of SeMet of 5 μM or more, substantially no cells survived.

Example 5Bystander Effect

A549 human lung cancer cells transduced with rAd-MET or control rAd (MOI 50) were mixed with non-transduced cells at various ratios in the presence of 20 µM SeMet.

- 5 Cytotoxicity was analyzed with the MTT assay described above after three (3) days. Figure 9 shows the results as a function of the percentage of infected cells. As shown, cells transduced with rAd either in the absence of SeMet or in the presence of SeMet, and cells transduced with rAd-MET in the absence of SeMet exhibited no ability to kill bystander cells. On the other hand, cells that had been transduced with rAd-MET were 10 able to destroy bystander cells in the presence of SeMet significantly even when they were present in the culture at a proportion as low as 1%. When present at 3.1% of the culture, these cells killed 80% of the non-transduced cells.

Example 6Confirmation of Apoptosis

- 15 A549 cells (1×10^6) were transduced with rAd-MET (MOI 20). After 24 hours, 20 µM SeMet was added. At various times, the cells were harvested and fixed with 70% ethanol and stained with 50 µg/ml propidium iodide. The DNA content of the stained cells was evaluated by FACS. As shown in figure 10, after 12 hours of exposure to SeMet, an increase in fluorescence labeling in the G₀ population was observed indicating the 20 presence of apoptotic cells. The proportion of these cells increased after 24 hours exposure to SeMet. The apoptotic effect was confirmed by electrophoresing the extracted DNA after 6, 12 and 24 hours. The electrophoresis results showed nucleosomal DNA fragmentation, confirming this result. It was also confirmed by showing cytochrome C release into the cytosol of cells infected with rAd-MET but not of cells infected with rAd.

25

Example 7ROS Generation

It is believed that selenium cytotoxicity is mediated by generation of reactive oxygen species (ROS). This can be measured by standard techniques which employ lucigenin-

dependent chemiluminescence as described by Yan, L., *et al.*, *Biochem Pharmacol* (1993) 45:429-437, cited above.

A549 cells were transduced with rAd-MET at MOI of 50, 24 hours before measurement.

The cells (1×10^6) were incubated in 1 ml RPMI in the presence of SeMet with or without

5 10 units of superoxide dismutase (SOD) for 30 minutes. Lucigenin (50 µg) was added to the cell suspension just prior to measurement and integrated chemiluminescence was measured for 10 seconds, three times, using a TD21 luminometer (Turner Designs).

Chemiluminescence levels were dependent on SeMet concentration and were inhibited by SOD. As shown in figure 11, chemiluminescence in the presence of 160 µM SeMet was 10 over 100 times that of the control and was inhibited by SOD. At 40 µM, it was 20 times control and inhibited by SOD.

The high level of oxidation was also confirmed by measuring GSH content. Cells (2×10^6) were infected with rAd-MET or control rAd at MOI of 20, 24 hours before treating with 20 µM SeMet. The cells were then lysed and then incubated with 0.05%

15 o-phthalaldehyde for 15 minutes and the GSH content was measured fluorometrically using 350 nM excitation and 420 nM emission. The glutathione content in cells transduced with control rAd remained substantially constant over 24 hours while the cells transduced with rAd-MET showed a reduction in GSH level from about 110 mg GSH/mg protein at time 0 to 80 mg/mg after 6 hours, 60 mg/mg after 12 hours and to less than 20 10 mg/mg after 24 hours.

Example 8

Mitochondrial Permeability

In further confirmation that the selenol poisoning is mediated by oxidation, advantage was taken of the known phenomenon whereby oxidants cause mitochondrial swelling and loss 25 of membrane potential (see, Green, D.R., *et al.*, *Science* (1998) 281:1309-1312; Cai, J., *et al.*, *Biochem Biophys Octa* (1998) 1366:139-149). It was confirmed that when cells were infected with rAd-MET (MOI 50) and later treated with 20 µM SeMet, after 24 hours incubation, the mitochondrial membranes were disrupted. Mitochondrial membrane potential changes were monitored with the fluorescence dye MitosensorTM which is 30 normally taken up in the mitochondria where it forms aggregates that exhibit intense red

fluorescence. In cells treated as described, MitosensorTM does not accumulate in the mitochondria and remains in the cytoplasm where it fluoresces green.

In an additional experiment, cells were treated as above except that an MOI of 20 was used. And the levels of caspase 3, caspase 8 and caspase 9 were measured at varying 5 times. As shown in figure 12, caspase 8 remained relatively constant but caspase 3 and caspase 9 in the lysates increased with time in the treated cells.

Further, mitochondrial swelling in the cells treated as described was visualized by electron microscopy; after 24 hours, most mitochondria were quite swollen.

Example 9

10 In Vivo Treatment

N1S1 rat hepatoma tumor cells (1×10^6 cells) were implanted into peritoneal cavities of female nude mice. Two days after implantation, either control rAd or rAd-MET (5×10^8 pfu) or mock control were injected every other day for a total of five (5) injections. The mice were also treated IP with either 1 μ M SeMet or normal saline daily 15 from day 3 to day 13. Ascites tumor growth was evaluated by body weight gain.

Figure 13 shows the results over 25 days. As shown, even over this period, the mice treated with rAd-MET and SeMet failed to gain significant amounts of weight. This was confirmed by observation, and, in figure 14, by the number of mice surviving as shown.

Example 10

20 Combined Effect of SeMet With Chemotherapeutic Agents

A549 cells that had been transfected with rAd-MET were cultured in RPMI with 20% FBS with and without 8 μ M SeMet. In each case, duplicate samples were cultured without BCNU and in the presence of 300 μ M BCNU. Cell survival was determined after 25 _____ hours. With no treatment, 100% of the cells survived; in the presence of SeMet alone, 80% of the cells survived. In the absence of SeMet, but in the presence of BCNU, 55% cell survival was obtained; in the presence of 8 μ M SeMet and 300 μ M BCNU, less than 10% of the cells survived. Thus, SeMet dramatically enhances the effect of BCNU. In a similar experiment, A549 cells that had been transfected with rAd-MET were cultured in RPMI with 10% FBS in the presence and absence of 4 μ M SeMet and with and without

0.4 μ M doxorubicin. In the presence of doxorubicin alone, a 75% cell survival rate was obtained; when SeMet was present alone, a 60% cell survival rate was obtained. However, a combination of these compounds resulted in cell survival of only 10%.

Claims

1. A method to inhibit the growth of tumor cells which method comprises treating said cells with a selenium prodrug lyase and a selenium-containing prodrug in amounts sufficient to inhibit said tumor cell growth.
- 5 2. The method of claim 1 wherein said selenium prodrug lyase is a methionine γ -lyase.
3. The method of claim 2 wherein said lyase is isolatable from *P. putida*.
4. The method of claim 1 wherein said lyase is provided in the form of a protein.
- 10 5. The method of claim 1 wherein said lyase is provided by treating with a nucleic acid molecule comprising an expression system for said lyase.
6. The method of claim 5 wherein said nucleic acid molecule is a viral vector.
7. The method of claim 6 wherein said vector is a retroviral vector.
8. The method of claim 1 wherein said selenium-containing prodrug is cysteine or homocysteine or the alkylated forms thereof wherein sulfur is replaced by selenium.
- 15 9. The method of claim 8 wherein said prodrug is selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
10. The method of claim 9 wherein said prodrug is selenomethionine.
- 20 11. The method of claim 1 wherein said tumor cells are present in an intact animal.

12. The method of claim 1 which further comprises treating said cells with a chemotherapeutic agent.

13. The method of claim 12 wherein said agent is BCNU.

1/9








FIG. 1

2/9



**FIG. 4****FIG. 5**

4/9




FIG. 6




FIG. 7

5/9





FIG. 9

6/9




FIG. 7

FIG. 10

7/9




FIG. 11




FIG. 12

9/9




FIG. 13




FIG. 14